BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 3131032)

  • 1. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA; Bernal SD; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
    Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
    Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.
    Teicher BA; Herman TS; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):286-91. PubMed ID: 3131033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents.
    Teicher BA; Holden SA
    Cancer Treat Rep; 1987 Feb; 71(2):173-7. PubMed ID: 3100035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity.
    Teicher BA; Crawford JM; Holden SA; Cathcart KN
    Cancer Res; 1987 Oct; 47(19):5036-41. PubMed ID: 3113727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Fluosol-DA/O2 on tumor-cell and bone-marrow cytotoxicity of nitrosoureas in mice bearing FSA-II fibrosarcoma.
    Teicher BA; Holden SA; Rose CM
    Int J Cancer; 1986 Aug; 38(2):285-8. PubMed ID: 3089945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of various oxygenation conditions and fluosol-DA on cytotoxicity and antitumor activity of bleomycin in mice.
    Teicher BA; Holden SA; Cathcart KN; Herman TS
    J Natl Cancer Inst; 1988 Jun; 80(8):599-603. PubMed ID: 2453675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity.
    Teicher BA; Holden SA; Jacobs JL
    Cancer Res; 1987 Jan; 47(2):513-8. PubMed ID: 3098413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation.
    Holden SA; Herman TS; Teicher BA
    Radiother Oncol; 1990 May; 18(1):59-70. PubMed ID: 2113698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by Fluosol-DA and oxygen breathing.
    Teicher BA; Holden SA; Rose CM
    Int J Cancer; 1985 Nov; 36(5):585-9. PubMed ID: 3932225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide.
    Teicher BA; Holden SA; Rose CM
    J Natl Cancer Inst; 1985 Dec; 75(6):1129-33. PubMed ID: 3934448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside.
    Teicher BA; Holden SA; Northey D; Dewhirst MW; Herman TS
    Int J Radiat Oncol Biol Phys; 1993 Apr; 26(1):103-9. PubMed ID: 8482616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
    Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
    Teicher BA; Holden SA; Ara G; Ha CS; Herman TS; Northey D
    J Cancer Res Clin Oncol; 1992; 118(7):509-14. PubMed ID: 1624542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of photodynamic therapy-induced hypoxia by fluosol-DA (20%) and carbogen breathing in mice.
    Fingar VH; Mang TS; Henderson BW
    Cancer Res; 1988 Jun; 48(12):3350-4. PubMed ID: 3130983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Fluosol-DA and oxygen breathing on adriamycin antitumor activity and cardiac toxicity in mice.
    Teicher BA; Holden SA; Crawford JM
    Cancer; 1988 Jun; 61(11):2196-201. PubMed ID: 3365649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo.
    Chaplin DJ; Horsman MR; Aoki DS
    Br J Cancer; 1991 Jan; 63(1):109-13. PubMed ID: 1846549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Fluosol-DA on the response of intracranial 9L tumors to X rays and BCNU.
    Teicher BA; Herman TS; Rose CM
    Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1187-92. PubMed ID: 3141321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for macrophage involvement in the enhancement of tumor growth delay with X-ray/Fluosol-DAR/O2 combination therapy.
    Holden SA; Teicher BA; McIntosh NL; Rose CM
    Anticancer Res; 1987; 7(3 Pt B):385-90. PubMed ID: 3115174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.